Kinaxo Enters into an Agreement with Boehringer Ingelheim
Kinaxo Biotechnologies GmbH announced that it has entered into a two-year collaboration with Boehringer Ingelheim. Under the agreement Kinaxo will apply its new platform technologies to studies on drug mode of action and target identification. Financial details of the agreement were not disclosed.
Building on its existing quantitative Cellular Target ProfilingTM capabilities, Kinaxo will now employ high end mass spectrometry-based technologies to quantitatively analyze post-translational modifications of proteins. This new service will make it possible to determine the effects of compounds on proteome-wide signal transduction pathways, providing a detailed and comprehensive picture of their in vivo mode of action in cultured cells or animal tissue. Such analyses will also facilitate identifying new biomarkers and drug targets.
In the initial phase of this collaboration Kinaxo will undertake two studies on behalf of Boehringer Ingelheim. The first will be a cell line analysis project to measure the effects of an enzyme inhibitor on the acetylation status of the cellular proteome. In the second study, Kinaxo will use its new phosphoproteomics platform to determine differences in the signal transduction pathway activation status of a specific neuronal tissue when comparing wild type with a genetically modified mouse strain modelling a defined disease state. The aim of this study is to identify new drug targets.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!

Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Last viewed contents
High-sensitivity bone marrow aspiration technology enhances leukemia cell detection
Multi-drug resistant infection spreading globally among cystic fibrosis patients

Like a Revolving Door: How Shuttling Proteins Operate Nuclear Pores

How a fungus hijacks our immune system - The pathogen lets humans fuel its own growth
Starpharma Launches New Start-Up Biotechnology Company

LGC acquires The Native Antigen Company - Strengthening LGC'S offer to the IVD sector

Merck Celebrates Topping-Out Ceremony for New Membrane Production Plant - Investment of more than € 140 million creates approximately 55 new jobs
First prize in DSM Awards for Chemistry and Technology 2006 presented to German researcher in the field of chemical biology

OSCAR detects cells in standby mode - New tool to better understand the biology of dormant stem cells

Yumda now part of LUMITOS - Europe’s leading provider of B2B portals has expanded its portfolio to media outlets for the food and beverage industries
Evonik Industries and BRAIN co-operate
